摘要
子宫内膜癌是比较常见的妇科恶性肿瘤，其中绝大部分是早期癌（Ⅰ和Ⅱ期，约占85％～90％）。晚期癌（Ⅲ和Ⅳ期）仅占10％～15％，但占内膜癌死亡的一半以上（约55％）。因此，改善晚期内膜癌的治疗是提高子宫内膜癌5年存活率（overal survival，OS）的关键。
出处
《中国生育健康杂志》
2007年第3期186-189,共4页
Chinese Journal of Reproductive Health
参考文献23
-
1Bristow RE,Zerbe MJ,Rosenshein NB,et al.Stage ⅣB endometrial carcinoma:the role of cytoreductive surgery and determinants of survival[J].Gynecol Oncol,2000,78:85-91. 被引量：1
-
2Behbakht K,Yordan EL,Casey C,et al.Prognostic indicators of survivalin advanced endometrial cancer[J].Gynecol Oncol,1994,55:363-367. 被引量：1
-
3Mariani A,Keeney GL,AleUi G,et al.Endometrial carcinoma:paraaortic dissemination[J].Gynecol Oncol,2004,92:833-838. 被引量：1
-
4Mundt AJ,Murphy KT,Rotmensch J,et al.Surgery and postoperative radiation therapy in HGO stage Ⅲ C endometrial carcinoma[J].Int J Radiation Oncology Biol Phys,2001,50(5):1154-1160. 被引量：1
-
5Mariani A,Webb MJ,Keeney GL,et al.Endometrial cancer:predictors of peritoneal failure[J].Gynecol Oncol,2003,89:236-242. 被引量：1
-
6Smith RS,Kapp DS,Chen Q,et al.Treatment of hish-risk uterine cancer with whole abdominal radiation therapy[J].Int J Radiation Oneology Biol Phys,2000,48(3):767-778. 被引量：1
-
7SuRon G,Axelrod JH,Bundy BN,et al.Whole abdominal radiotherapy in the adjuvant treatment of patients with stage Ⅲ and Ⅳ endometrial cancer:a GOG study[J].Gynecol Oncol,2005,97:755-763 被引量：1
-
8Aoki Y,Kase H,Watanabe M,et al.Stage Ⅲ endometrial cancer:analysis of prognostic factors and failure patterns after adjuvant chemotherapy[J].Gynecol Oncol,2001,83:1-5. 被引量：1
-
9Mundt AJ,McBride R,Rotmensch J,et al.Significant pelvic recurrence in high-risk pathologic stage Ⅰ-Ⅳ endometrial carcinon patients after adjuvant chemotherapy alone:implications for adjuvant radiation therapy[J].hat J Radiation Oneology Biol Phys,200150(5):1145-1153. 被引量：1
-
10Bruzzone M,Miglieua L,Franzone P,et al.Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage Ⅲ-Ⅳ endometrial cancer patients[J].Gyneeol Oncol,2004,93:345-352. 被引量：1
同被引文献20
-
1孔北华,宋坤.卵巢癌的巩固化疗[J].实用妇产科杂志,2005,21(5):264-265. 被引量：2
-
2Rebecca L, Siege M, Kimberly D, et al. Cancer Statistics,2016 [ J]. CA Cancer J Clin,2015,66( 1 ) :7-30. 被引量：1
-
3Celia D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer : Results from GOG 184 [ J ]. Gynecol Oncol, 2010, 119 ( 3 ) :538-542. 被引量：1
-
4Fleming GF,Brunetto VL,Cella D,et al. Phase III trial of doxorubi- tin plus cisplatin with or without paclitaxel plus filgrastim in ad- vanced endometrial carcinoma:a Gynecologic Ontology Group Study [ J]. J Clin Oncol,2004,22 ( 11 ) :2159-2166. 被引量：1
-
5Millel VF,Fleming RM,Cohn TM,et al. Randomized phase III non- inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [ J]. Gvnecol Oncol, 2012.125 ( 3 ):771. 被引量：1
-
6Poplin EA, Liu PY, Delmore JE, et al. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest ontology group study[ J]. Gynecol Oncol, 1999,74( 3 ) :432-435. 被引量：1
-
7Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcino- ma: Eastern Cooperative Oncology Group Study E3E93 [ J]. J Clin Oncol,2003,21 ( 11 ) :2110-2114. 被引量：1
-
8Miller DS, Blessing JA,Lentz SS, et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carci- noma : a gynecologic oncology group study [ J ]. Gynecol Oncol,2002, 87(3) :247-251. 被引量：1
-
9Von PJ, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of o- ral versus intravenous topoteean in patients with chemosensitive small-cell lung cancer [ J ]. J Clin Oneo1,2001,19 (6) : 1743 - 1749. 被引量：1
-
10Gore M,Oza A,Rustin G,et al. A randomised trial of oral versus in- travenous topotecan in patients with relapsed epithelial ovarian canc- er[J]. Eur J Cancer,2002,38( 1 ) :57-63. 被引量：1
引证文献2
-
1李泓佳,石齐,李文,刘珊珊,宗绍其,侯风刚.具有高危因素、多次复发的子宫内膜癌及文献综述[J].中国临床医生杂志,2016,44(6):37-40. 被引量：3
-
2张坤,郭红燕,韩劲松.22例子宫内膜癌复发病例的临床特点分析[J].中国微创外科杂志,2017,17(6):495-497. 被引量：5
二级引证文献8
-
1张坤,郭红燕,韩劲松.22例子宫内膜癌复发病例的临床特点分析[J].中国微创外科杂志,2017,17(6):495-497. 被引量：5
-
2韩肖彤,刘晨,李锐锐,王永军.子宫内膜样腺癌术后再发阴道未分化多形性肉瘤1例及文献分析[J].中国微创外科杂志,2018,18(6):567-571. 被引量：2
-
3刘华,尚淑平,王敏.101例子宫内膜癌肿瘤转移的高危因素分析[J].实用癌症杂志,2020,35(2):286-288. 被引量：3
-
4李荣,卢余莉,李永利.肾静脉水平腹主动脉旁淋巴结清扫对非Ⅰ期子宫内膜癌手术患者术后复发的影响[J].华南国防医学杂志,2020,34(1):61-63. 被引量：7
-
5王彩丽,赵锦丽.宫腔镜电切术联合地屈孕酮治疗子宫内膜癌的疗效及术后复发的相关影响因素分析[J].实用癌症杂志,2020,35(6):1019-1022. 被引量：23
-
6周蔚,戴晓云,王中海.STC2蛋白在子宫内膜癌中的表达及其与预后的关系[J].蚌埠医学院学报,2020,45(10):1384-1386. 被引量：3
-
7王亚玲.子宫内膜癌患者外周血HMGA1、CK19和CK20水平分析[J].中国生育健康杂志,2021,32(6):574-576. 被引量：2
-
8曹萌青,钟梅,钱延玲.CA125与HE4联合检测在子宫内膜癌诊断与治疗中的研究进展[J].健康之路,2016,0(12):23-23.
-
1浦建文,赵锦华,袁勇.联合化疗治疗晚期子宫内膜癌的临床分析[J].实用肿瘤学杂志,1992,6(4):35-35.
-
2晚期子宫内膜癌[J].实用妇产科杂志,1989,5(1):12-14.
-
3谭玉婷,沙孝珍.晚期子宫内膜癌的治疗进展[J].中国医学文摘（肿瘤学）,2001,15(4):360-362. 被引量：3
-
4赵轶敏.CT联合MRI检查在晚期子宫内膜癌术前分期中的应用价值分析[J].中国医药指南,2016,14(11):152-153. 被引量：8
-
5岳松滨,吴其林,王瑞征,王勇.中西医结合治疗晚期恶性肿瘤的疗效观察[J].西南国防医药,1999,9(4):245-246. 被引量：2
-
6王镇南,唐志,李淑慧,詹德超,杨东红.新辅助化疗治疗晚期子宫内膜癌的效果观察[J].齐齐哈尔医学院学报,2015,36(7):958-960. 被引量：8
-
7崔鹤仙,刘增辉,牛红梅,单晓萍,崔桂荣,李焱.岩舒注射液辅助治疗晚期子宫内膜癌的疗效观察[J].山东医药,2011,51(1):63-64. 被引量：3
-
8王鹤,陈心秋,黄薇,李菲,姚德生,高琨,潘忠勉.晚期子宫内膜癌术后辅助放疗的临床观察[J].微创医学,2007,2(5):404-405. 被引量：3
-
9贺强.介入治疗晚期癌35例近期疗效分析[J].实用医技杂志,2001,8(5):398-398.
-
10崔永琼.联合应用CT和MRI在晚期子宫内膜癌术前分期中的应用价值分析[J].中外女性健康研究,2016(6):1-2. 被引量：5
